Compare Enveric Biosciences Inc (ENVB) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Fidelity National Information Servcs Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Fidelity National Information Servcs Inc trades at $34.04 (market cap $17.71B). The key difference: Fidelity National Information Servcs Inc is far larger — about 2604.4× Enveric Biosciences Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Fidelity National Information Servcs Inc for 88 Days on average.
| ENVB | FIS | |
|---|---|---|
Market Cap | $6.80M | $17.71B |
Volume | 64,867 | 9,047,825 |
Sector | Health | Technology |
52-Week High | $10.80 | $67.94 |
52-Week Low | $1.27 | $32.44 |
Typical Hold Time | 14 Days | 88 Days |
Enterprise Value | -$1.49M | $38.22B |
Dividend Yield | — | 5.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.52, up 1.67% with a bearish technical outlook despite recent earnings beats. The company shows no revenue but has improved quarterly EPS performance, with Q4 2025 turning positive. Analyst sentiment is bullish with 75% buy ratings, while technical indicators show selling pressure with 15 sell signals versus 1 buy.
Investment outlook remains speculative given negative profitability metrics and zero revenue, though patent developments and FDA guidance provide potential catalysts. Key risks include cash burn and clinical trial outcomes, while institutional support through financing offers near-term stability.
FIS trades at $34.34, up 1.54% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth from $10.68B in 2025 to projected $12.2B in 2026 and net income margin expanding to 27.65%. Recent business wins include core banking platform selections and embedded banking launches, positioning FIS for modernization growth. Analyst consensus remains strongly bullish with a $47.15 price target representing 37% upside potential.
FIS presents a compelling value opportunity with attractive valuation multiples (P/E 5.27, P/S 1.46) and strong analyst support, though investors face risks from negative cash flow trends, high debt levels, and technical bearish signals. The company's strategic positioning in banking technology modernization provides growth catalysts, but execution risks and market volatility require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
